Ivermectin for COVID-19: real-time meta analysis of 63 studies

… the probability that an ineffective treatment generated results as positive as the 63 studies is estimated to be 1 in 1 trillion

… Those denying the efficacy of treatments share responsibility

… The evidence base is much larger … than typically used to approve drugs

… Merck has a ~$1.2B agreement to supply molnupiravir to the US government, if it receives EUA or approval

… Ivermectin is off-patent

… Japan requested Merck conduct clinical trials early in the pandemic and they declined